Intuitive Surgical

ISRG

Market cap $179B

Both ISRG and ABT closed 2025 on a strong note, but Intuitive Surgical's surging procedure growth and innovation may give it the edge for long-term gains.

Intuitive Surgical's expanding installed base of surgical robots has made it a very popular stock. More diversified competitor Medtronic also offers its own surgical robot.

Tesla is banking its future on unsupervised full self-driving technology and Optimus robots. Intuitive Surgical's da Vinci systems have been used in more than 20 million procedures.

Nvidia's bold CES 2026 push into physical AI underscores a robotics boom as funding, factory adoption and humanoid rollouts fuel a pivotal growth cycle.

ISRG, EW and ELMD tap GenAI to enhance diagnostics and workflows, even as MedTech faces cost pressures, data risks and macro headwinds.

Intuitive Surgical can overcome recent headwinds thanks to its robust competitive edge. The robotics-assisted surgery specialist still has significant growth avenues ahead of it.

Novo Nordisk's GLP-1 pill has reignited the competition in the GLP-1 space. But you can sidestep that drama by buying this surgical robotics pioneer.

Intuitive Surgical sees international procedures jump 23% in 2025, now 35% of total, outpacing U.S. growth and reshaping its long-term expansion strategy.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Intuitive Surgical dominates the robotic surgery market. The company sells surgical platforms, accessories, and service contracts.